Nalidixic acid plus sodium citrate twice daily in the treatment of acute urinary tract infection. Swedish Collaborative Study Group.
Negram-Citrat (0.66 g nalidixic acid plus 4 g sodium citrate, NAC) twice daily for five days was evaluated in 257 women with symptoms of acute lower urinary tract infection and nalidixic acid sensitive bacteriuria. At two days post-treatment 85% of the patients were abacteriuric while nalidixic acid resistant Escherichia coli bacteriuria was present in five %. Side effects of NAC were usually mild and transient and resulted in interruption of medication in three % of the patients and visual disturbances were volunteered by 1.6%. At follow-up one month after treatment bacteriuria had recurred in 18% of the patients immediately cured, thus resulting in an overall success rate of 70%. Of the 35 recurring strains three (1 E. coli, 2 Staphylococcus epidermidis) were nalidixic acid resistant.
D042462:4-Quinolones; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents; D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001437:Bacteriuria / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D008875:Middle Aged; D009268:Nalidixic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012008:Recurrence; D014552:Urinary Tract Infections / Q000188:drug therapy*
D042462:4-Quinolones; D000890:Anti-Infective Agents; D000892:Anti-Infective Agents, Urinary; D004338:Drug Combinations; D009268:Nalidixic Acid; C028959:citrated nalidixic acid